Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
288tsGpD9m6cxCLu
